506 related articles for article (PubMed ID: 1723153)
1. Mechanism underlying the reduced positive inotropic effects of the phosphodiesterase III inhibitors pimobendan, adibendan and saterinone in failing as compared to nonfailing human cardiac muscle preparations.
von der Leyen H; Mende U; Meyer W; Neumann J; Nose M; Schmitz W; Scholz H; Starbatty J; Stein B; Wenzlaff H
Naunyn Schmiedebergs Arch Pharmacol; 1991 Jul; 344(1):90-100. PubMed ID: 1723153
[TBL] [Abstract][Full Text] [Related]
2. Effects of isomazole on force of contraction and phosphodiesterase isoenzymes I-IV in nonfailing and failing human hearts.
Bethke T; Klimkiewicz A; Kohl C; von der Leyen H; Mehl H; Mende U; Meyer W; Neumann J; Schmitz W; Scholz H
J Cardiovasc Pharmacol; 1991 Sep; 18(3):386-97. PubMed ID: 1720839
[TBL] [Abstract][Full Text] [Related]
3. Phosphodiesterase inhibition and positive inotropy in failing human myocardium.
Schmitz W; Eschenhagen T; Mende U; Müller FU; Neumann J; Scholz H
Basic Res Cardiol; 1992; 87 Suppl 1():65-71. PubMed ID: 1323266
[TBL] [Abstract][Full Text] [Related]
4. Contribution of cAMP-phosphodiesterase inhibition and sensitization of the contractile proteins for calcium to the inotropic effect of pimobendan in the failing human myocardium.
Böhm M; Morano I; Pieske B; Rüegg JC; Wankerl M; Zimmermann R; Erdmann E
Circ Res; 1991 Mar; 68(3):689-701. PubMed ID: 1660359
[TBL] [Abstract][Full Text] [Related]
5. Reduced alpha 1- and beta 2-adrenoceptor-mediated positive inotropic effects in human end-stage heart failure.
Steinfath M; Danielsen W; von der Leyen H; Mende U; Meyer W; Neumann J; Nose M; Reich T; Schmitz W; Scholz H
Br J Pharmacol; 1992 Feb; 105(2):463-9. PubMed ID: 1348446
[TBL] [Abstract][Full Text] [Related]
6. Effects of saterinone and its enantiomers R(+)-saterinone and S(-)-saterinone on the phosphodiesterase isoenzymes from ventricular tissue of failing human hearts and porcine hearts.
Zimmermann W; Scholz H; Schumacher C; Wenzlaff H; Haverich A
Naunyn Schmiedebergs Arch Pharmacol; 1994 Jun; 349(6):611-8. PubMed ID: 7526225
[TBL] [Abstract][Full Text] [Related]
7. EMD 53998 acts as Ca(2+)-sensitizer and phosphodiesterase III-inhibitor in human myocardium.
Uhlmann R; Schwinger RH; Lues I; Erdmann E
Basic Res Cardiol; 1995; 90(5):365-71. PubMed ID: 8585857
[TBL] [Abstract][Full Text] [Related]
8. Selective inhibition of cAMP phosphodiesterase III activity by the cardiotonic agent saterinone in guinea pig myocardium.
Brunkhorst D; von der Leyen H; Meyer W; Schmidt-Schumacher C; Scholz H
Arzneimittelforschung; 1988 Sep; 38(9):1293-8. PubMed ID: 2852013
[TBL] [Abstract][Full Text] [Related]
9. Mechanism of action and cardiotonic activity of a new phosphodiesterase inhibitor, the benzimidazole derivative adibendan (BM 14.478), in guinea-pig hearts.
Bethke T; Brunkhorst D; von der Leyen H; Meyer W; Nigbur R; Scholz H
Naunyn Schmiedebergs Arch Pharmacol; 1988 May; 337(5):576-82. PubMed ID: 2457816
[TBL] [Abstract][Full Text] [Related]
10. Effects of the benzimidazole derivatives pimobendan and 2-(4-hydroxy-phenyl)-5-(5-methyl-3-oxo-4,5-dihydro-2H-6- pyridazinyl) benzimidazole . HCl on phosphodiesterase activity and force of contraction in guinea-pig hearts.
Berger C; Meyer W; Scholz H; Starbatty J
Arzneimittelforschung; 1985; 35(11):1668-73. PubMed ID: 2418846
[TBL] [Abstract][Full Text] [Related]
11. Positive inotropic effects in isolated ventricular myocardium from non-failing and terminally failing human hearts.
Näbauer M; Böhm M; Brown L; Diet F; Eichhorn M; Kemkes B; Pieske B; Erdmann E
Eur J Clin Invest; 1988 Dec; 18(6):600-6. PubMed ID: 2465159
[TBL] [Abstract][Full Text] [Related]
12. Effect of inotropic interventions on the force-frequency relation in the human heart.
Bavendiek U; Brixius K; Münch G; Zobel C; Müller-Ehmsen J; Schwinger RH
Basic Res Cardiol; 1998; 93 Suppl 1():76-85. PubMed ID: 9833134
[TBL] [Abstract][Full Text] [Related]
13. Characterization of the phosphodiesterase inhibition by 2-(3-methoxy-5-methylsulfinyl-2-thienyl)-1H-imidazo-(4,5-c)-pyridine HCl and its sulfide- and sulfone derivatives in myocardial preparations from failing human hearts.
Bethke T; Klimkiewicz A; Meyer W; Schumacher C; Schmitz W; Scholz H; Starbatty J; Wenzlaff H; Zimmermann W
Arzneimittelforschung; 1995 Jul; 45(7):771-6. PubMed ID: 8573220
[TBL] [Abstract][Full Text] [Related]
14. Incomplete reversal of beta-adrenoceptor desensitization in human and guinea-pig cardiomyocytes by cyclic nucleotide phosphodiesterase inhibitors.
Wynne DG; Poole-Wilson PA; Harding SE
Br J Pharmacol; 1993 Aug; 109(4):1071-8. PubMed ID: 7691363
[TBL] [Abstract][Full Text] [Related]
15. Relation of positive inotropic and chronotropic effects of pimobendan, UD-CG 212 Cl, milrinone and other phosphodiesterase inhibitors to phosphodiesterase III inhibition in guinea-pig heart.
Brunkhorst D; v der Leyen H; Meyer W; Nigbur R; Schmidt-Schumacher C; Scholz H
Naunyn Schmiedebergs Arch Pharmacol; 1989 May; 339(5):575-83. PubMed ID: 2549430
[TBL] [Abstract][Full Text] [Related]
16. Phosphodiesterase inhibition by enoximone in preparations from nonfailing and failing human hearts.
Bethke T; Eschenhagen T; Klimkiewicz A; Kohl C; von der Leyen H; Mehl H; Mende U; Meyer W; Neumann J; Rosswag S
Arzneimittelforschung; 1992 Apr; 42(4):437-45. PubMed ID: 1386515
[TBL] [Abstract][Full Text] [Related]
17. Protein phosphorylation in isolated trabeculae from nonfailing and failing human hearts.
Bartel S; Stein B; Eschenhagen T; Mende U; Neumann J; Schmitz W; Krause EG; Karczewski P; Scholz H
Mol Cell Biochem; 1996 Apr 12-26; 157(1-2):171-9. PubMed ID: 8739244
[TBL] [Abstract][Full Text] [Related]
18. Effects of several newer cardiotonic drugs on cardiac cyclic AMP metabolism.
Ahn HS; Eardley D; Watkins R; Prioli N
Biochem Pharmacol; 1986 Apr; 35(7):1113-21. PubMed ID: 2421728
[TBL] [Abstract][Full Text] [Related]
19. The two mechanisms of action of racemic cardiotonic EMD 53998, calcium sensitization and phosphodiesterase inhibition, reside in different enantiomers.
Lues I; Beier N; Jonas R; Klockow M; Haeusler G
J Cardiovasc Pharmacol; 1993 Jun; 21(6):883-92. PubMed ID: 7687712
[TBL] [Abstract][Full Text] [Related]
20. Calcium sensitization as new principle of inotropic therapy in end-stage heart failure?
Zimmermann N; Boknik P; Gams E; Herzig JW; Neumann J; Scholz H
Eur J Cardiothorac Surg; 1998 Jul; 14(1):70-5. PubMed ID: 9726618
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
